Adipokine C1q/Tumor Necrosis Factor- Related Protein 3 (CTRP3) Attenuates Intestinal Inflammation Via Sirtuin 1/NF-κB Signaling.
Adipokine CTRP3
IBD
Intestinal Inflammation
Intestinal organoids
SIRT1/NF-κB Signaling
Journal
Cellular and molecular gastroenterology and hepatology
ISSN: 2352-345X
Titre abrégé: Cell Mol Gastroenterol Hepatol
Pays: United States
ID NLM: 101648302
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
09
2022
revised:
21
12
2022
accepted:
21
12
2022
pubmed:
3
1
2023
medline:
22
3
2023
entrez:
2
1
2023
Statut:
ppublish
Résumé
The adipokine CTRP3 has anti-inflammatory effects in several nonintestinal disorders. Although serum CTRP3 is reduced in patients with inflammatory bowel disease (IBD), its function in IBD has not been established. Here, we elucidate the function of CTRP3 in intestinal inflammation. CTRP3 knockout (KO) and overexpressing transgenic (Tg) mice, along with their corresponding wild-type littermates, were treated with dextran sulfate sodium for 6-10 days. Colitis phenotypes and histologic data were analyzed. CTRP3-mediated signaling was examined in murine and human intestinal mucosa and mouse intestinal organoids derived from CTRP3 KO and Tg mice. CTRP3 KO mice developed more severe colitis, whereas CTRP3 Tg mice developed less severe colitis than wild-type littermates. The deletion of CTRP3 correlated with decreased levels of Sirtuin-1 (SIRT1), a histone deacetylase, and increased levels of phosphorylated/acetylated NF-κB subunit p65 and proinflammatory cytokines tumor necrosis factor-α and interleukin-6. Results from CTRP3 Tg mice were inverse to those from CTRP3 KO mice. The addition of SIRT1 activator resveratrol to KO intestinal organoids and SIRT1 inhibitor Ex-527 to Tg intestinal organoids suggest that SIRT1 is a downstream effector of CTRP3-related inflammatory changes. In patients with IBD, a similar CTRP3/SIRT1/NF-κB relationship was observed. CTRP3 expression levels correlate negatively with intestinal inflammation in acute mouse colitis models and patients with IBD. CTRP3 may attenuate intestinal inflammation via SIRT1/NF-κB signaling. The manipulation of CTRP3 signaling, including through the use of SIRT1 activators, may offer translational potential in the treatment of IBD.
Sections du résumé
BACKGROUND & AIMS
The adipokine CTRP3 has anti-inflammatory effects in several nonintestinal disorders. Although serum CTRP3 is reduced in patients with inflammatory bowel disease (IBD), its function in IBD has not been established. Here, we elucidate the function of CTRP3 in intestinal inflammation.
METHODS
CTRP3 knockout (KO) and overexpressing transgenic (Tg) mice, along with their corresponding wild-type littermates, were treated with dextran sulfate sodium for 6-10 days. Colitis phenotypes and histologic data were analyzed. CTRP3-mediated signaling was examined in murine and human intestinal mucosa and mouse intestinal organoids derived from CTRP3 KO and Tg mice.
RESULTS
CTRP3 KO mice developed more severe colitis, whereas CTRP3 Tg mice developed less severe colitis than wild-type littermates. The deletion of CTRP3 correlated with decreased levels of Sirtuin-1 (SIRT1), a histone deacetylase, and increased levels of phosphorylated/acetylated NF-κB subunit p65 and proinflammatory cytokines tumor necrosis factor-α and interleukin-6. Results from CTRP3 Tg mice were inverse to those from CTRP3 KO mice. The addition of SIRT1 activator resveratrol to KO intestinal organoids and SIRT1 inhibitor Ex-527 to Tg intestinal organoids suggest that SIRT1 is a downstream effector of CTRP3-related inflammatory changes. In patients with IBD, a similar CTRP3/SIRT1/NF-κB relationship was observed.
CONCLUSIONS
CTRP3 expression levels correlate negatively with intestinal inflammation in acute mouse colitis models and patients with IBD. CTRP3 may attenuate intestinal inflammation via SIRT1/NF-κB signaling. The manipulation of CTRP3 signaling, including through the use of SIRT1 activators, may offer translational potential in the treatment of IBD.
Identifiants
pubmed: 36592863
pii: S2352-345X(22)00264-8
doi: 10.1016/j.jcmgh.2022.12.013
pmc: PMC10040965
pii:
doi:
Substances chimiques
Adipokines
0
Complement C1q
80295-33-6
NF-kappa B
0
Sirtuin 1
EC 3.5.1.-
Tumor Necrosis Factor-alpha
0
CORS26 protein, mouse
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1000-1015Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK084171
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK089502
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Intest Res. 2020 Oct;18(4):379-401
pubmed: 32259917
Diabetes. 2012 Nov;61(11):2932-6
pubmed: 22837306
J Mol Cell Cardiol. 2018 Jan;114:38-47
pubmed: 29061338
Cells. 2019 Jun 21;8(6):
pubmed: 31234447
Intest Res. 2020 Apr;18(2):144-150
pubmed: 32326668
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10302-7
pubmed: 15231994
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7
pubmed: 26323879
Autoimmun Rev. 2014 Jan;13(1):3-10
pubmed: 23774107
Gut. 2019 Jun;68(6):1115-1126
pubmed: 30944110
Lab Invest. 1993 Aug;69(2):238-49
pubmed: 8350599
J Biol Chem. 2001 Feb 2;276(5):3628-34
pubmed: 11071891
Int J Mol Sci. 2020 Dec 15;21(24):
pubmed: 33334069
Gastroenterology. 1998 Aug;115(2):357-69
pubmed: 9679041
Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S77-8
pubmed: 18816772
Inflamm Bowel Dis. 2020 Mar 4;26(4):619-625
pubmed: 31504515
PLoS One. 2016 Oct 11;11(10):e0164593
pubmed: 27727322
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):238-247
pubmed: 28404096
Br J Surg. 1992 Sep;79(9):955-8
pubmed: 1422768
Biochem J. 2008 Dec 1;416(2):161-77
pubmed: 18783346
Trends Endocrinol Metab. 2012 Apr;23(4):194-204
pubmed: 22261190
Gut. 2007 Apr;56(4):577-83
pubmed: 16956921
PLoS One. 2014 Jul 11;9(7):e102495
pubmed: 25013930
MMWR Morb Mortal Wkly Rep. 2016 Oct 28;65(42):1166-1169
pubmed: 27787492
J Mol Med (Berl). 2015 Dec;93(12):1311-25
pubmed: 26138247
Inflamm Bowel Dis. 2006 Jun;12(6):471-7
pubmed: 16775490
Gastroenterology. 1999 Jul;117(1):73-81
pubmed: 10381912
Nat Rev Immunol. 2008 Jun;8(6):458-66
pubmed: 18500230
Pharmacol Rep. 2019 Feb;71(1):105-111
pubmed: 30513401
Gastroenterology. 2020 Aug;159(2):591-608.e10
pubmed: 32428507
J Mt Sinai Hosp N Y. 1955 Sep-Oct;22(3):147-58
pubmed: 13252395
Genes Immun. 2019 Sep;20(7):577-588
pubmed: 30692607
Diabetol Metab Syndr. 2015 Apr 10;7:33
pubmed: 25878729
Gut. 2013 Jun;62(6):852-62
pubmed: 22543156
Front Med (Lausanne). 2018 Feb 19;5:32
pubmed: 29515999
Trends Immunol. 2007 Sep;28(9):393-9
pubmed: 17681884
Am J Physiol Endocrinol Metab. 2016 Mar 1;310(5):E332-45
pubmed: 26670485
Diabetes Res Clin Pract. 2005 Jul;69(1):29-35
pubmed: 15955385
IUBMB Life. 2020 Aug;72(8):1698-1704
pubmed: 32311832
Compr Physiol. 2017 Jun 18;7(3):863-878
pubmed: 28640446
J Biol Chem. 2010 Dec 17;285(51):39691-701
pubmed: 20952387
Mucosal Immunol. 2014 Nov;7(6):1467-79
pubmed: 24850427
J Crohns Colitis. 2018 Jun 28;12(7):794-803
pubmed: 29608662
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8766-71
pubmed: 19443690
Gastroenterology. 2019 Mar;156(4):1082-1097.e11
pubmed: 30452921
Am J Physiol Cell Physiol. 2020 Aug 1;319(2):C321-C330
pubmed: 32551856
Inflamm Bowel Dis. 2011 Dec;17(12):2462-71
pubmed: 21351204
Biosci Rep. 2020 Oct 30;40(10):
pubmed: 32219332
Mt Sinai J Med. 2000 May;67(3):263-8
pubmed: 10828911
PeerJ. 2016 Oct 18;4:e2573
pubmed: 27781167
PLoS One. 2015 Jul 29;10(7):e0133955
pubmed: 26222183
Biochem Biophys Res Commun. 2014 Jan 3;443(1):42-8
pubmed: 24269820
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Cell. 2020 Oct 29;183(3):666-683.e17
pubmed: 32991841
J Crohns Colitis. 2017 Jan;11(1):92-104
pubmed: 27364949
PLoS One. 2014 Jun 26;9(6):e99785
pubmed: 24968098
Gastroenterology. 2017 Sep;153(3):772-786
pubmed: 28552621
PLoS One. 2014 Nov 19;9(11):e112931
pubmed: 25409499
PLoS One. 2013;8(2):e55744
pubmed: 23409033
Physiol Rep. 2016 Mar;4(5):
pubmed: 26997632
Am J Physiol Gastrointest Liver Physiol. 2013 Aug 1;305(3):G214-24
pubmed: 23744740
Gut. 1998 Apr;42(4):477-84
pubmed: 9616307
Nat Protoc. 2013 Sep;8(9):1743-58
pubmed: 23949380